| pubmed-article:16691490 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16691490 | lifeskim:mentions | umls-concept:C0242738 | lld:lifeskim |
| pubmed-article:16691490 | lifeskim:mentions | umls-concept:C0185026 | lld:lifeskim |
| pubmed-article:16691490 | lifeskim:mentions | umls-concept:C0243067 | lld:lifeskim |
| pubmed-article:16691490 | lifeskim:mentions | umls-concept:C2828102 | lld:lifeskim |
| pubmed-article:16691490 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:16691490 | pubmed:dateCreated | 2006-5-12 | lld:pubmed |
| pubmed-article:16691490 | pubmed:abstractText | The ATP-binding cassette (ABC) family of membrane transport proteins is the largest class of transporters in humans (48 members). The majority of ABC transporters function at the cell surface. Therefore, defective folding and trafficking of the protein to the cell surface can lead to serious health problems. The classic example is cystic fibrosis (CF). In most CF patients, there is a deletion of Phe508 in the CFTR protein (DeltaF508 CFTR) that results in defective folding and intracellular retention of the protein (processing mutant). A potential treatment for most patients with CF would be to use a ligand(s) of CFTR that acts a pharmacological chaperone to correct the folding defect. The feasibility of such an approach was first demonstrated with the multidrug transporter P-glycoprotein (P-gp), an ABC transporter, and a sister protein of CFTR. It was found that P-gps with mutations at sites equivalent to those found in CFTR processing mutants were rescued when they were expressed in the presence of drug substrates or modulators of P-gp. These compounds acted as pharmacological chaperones and functioned by promoting interactions among the various domains in the protein during the folding process. Several groups have attempted to identify compounds that could rescue the folding defect in DeltaF508 CFTR. The best compound identified through high-throughout screening is a quinazoline derivative (CFcor-325). Expression of DeltaF508 CFTR as well as other CFTR processing mutants in the presence of 1 muM CFcor-325 promoted folding and trafficking of the mutant proteins to the cell surface in an active conformation. Therefore, CFcor-325 and other quinazoline derivates could be important therapeutic compounds for the treatment of CF. | lld:pubmed |
| pubmed-article:16691490 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16691490 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16691490 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16691490 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16691490 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16691490 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16691490 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16691490 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16691490 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:16691490 | pubmed:issn | 0145-479X | lld:pubmed |
| pubmed-article:16691490 | pubmed:author | pubmed-author:LooTip WTW | lld:pubmed |
| pubmed-article:16691490 | pubmed:author | pubmed-author:ClarkeDavid... | lld:pubmed |
| pubmed-article:16691490 | pubmed:author | pubmed-author:BartlettM... | lld:pubmed |
| pubmed-article:16691490 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16691490 | pubmed:volume | 37 | lld:pubmed |
| pubmed-article:16691490 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16691490 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16691490 | pubmed:pagination | 501-7 | lld:pubmed |
| pubmed-article:16691490 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16691490 | pubmed:meshHeading | pubmed-meshheading:16691490... | lld:pubmed |
| pubmed-article:16691490 | pubmed:meshHeading | pubmed-meshheading:16691490... | lld:pubmed |
| pubmed-article:16691490 | pubmed:meshHeading | pubmed-meshheading:16691490... | lld:pubmed |
| pubmed-article:16691490 | pubmed:meshHeading | pubmed-meshheading:16691490... | lld:pubmed |
| pubmed-article:16691490 | pubmed:meshHeading | pubmed-meshheading:16691490... | lld:pubmed |
| pubmed-article:16691490 | pubmed:meshHeading | pubmed-meshheading:16691490... | lld:pubmed |
| pubmed-article:16691490 | pubmed:meshHeading | pubmed-meshheading:16691490... | lld:pubmed |
| pubmed-article:16691490 | pubmed:meshHeading | pubmed-meshheading:16691490... | lld:pubmed |
| pubmed-article:16691490 | pubmed:meshHeading | pubmed-meshheading:16691490... | lld:pubmed |
| pubmed-article:16691490 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16691490 | pubmed:articleTitle | Rescue of folding defects in ABC transporters using pharmacological chaperones. | lld:pubmed |
| pubmed-article:16691490 | pubmed:affiliation | Department of Medicine, University of Toronto, Rm. 7342, Medical Sciences Building, 1 King's College Circle, Toronto, Ontario, Canada. | lld:pubmed |
| pubmed-article:16691490 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16691490 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:16691490 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16691490 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16691490 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16691490 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16691490 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16691490 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16691490 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16691490 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16691490 | lld:pubmed |
